Douglas T. Fearon

41.9k total citations · 10 hit papers
178 papers, 24.5k citations indexed

About

Douglas T. Fearon is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Douglas T. Fearon has authored 178 papers receiving a total of 24.5k indexed citations (citations by other indexed papers that have themselves been cited), including 129 papers in Immunology, 38 papers in Molecular Biology and 38 papers in Oncology. Recurrent topics in Douglas T. Fearon's work include T-cell and B-cell Immunology (54 papers), Complement system in diseases (49 papers) and Immune Cell Function and Interaction (46 papers). Douglas T. Fearon is often cited by papers focused on T-cell and B-cell Immunology (54 papers), Complement system in diseases (49 papers) and Immune Cell Function and Interaction (46 papers). Douglas T. Fearon collaborates with scholars based in United States, United Kingdom and Portugal. Douglas T. Fearon's co-authors include Johanna A. Joyce, Richard M. Locksley, K. Frank Austen, David A. Tuveson, Robert H. Carter, Edward W. Roberts, Matthew Kraman, Michael C. Carroll, K. Frank Austen and Joseph M. Ahearn and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Douglas T. Fearon

178 papers receiving 23.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

T cell exclusion, immune privilege, and the tumor microenvironment

2015 1.7k citations Douglas T. Fearon et al. Science profile →
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer

2013 1.5k citations James O. Jones, Matthew Kraman et al. Proceedings of the National Academy of Sciences profile →
The Instructive Role of Innate Immunity in the Acquired Immune Response

1996 1.3k citations Douglas T. Fearon et al. Science profile →
C3d of Complement as a Molecular Adjuvant: Bridging Innate and Acquired Immunity

1996 941 citations Douglas T. Fearon et al. Science profile →
Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α

2010 918 citations Matthew Kraman, James N. Arnold et al. Science profile →
Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I

2020 844 citations Douglas T. Fearon et al. profile →
Soluble Human Complement Receptor Type 1: In Vivo Inhibitor of Complement Suppressing Post-Ischemic Myocardial Inflammation and Necrosis

1990 793 citations Douglas T. Fearon et al. Science profile →
Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2.

1984 720 citations Douglas T. Fearon et al. Proceedings of the National Academy of Sciences profile →
CD19: Lowering the Threshold for Antigen Receptor Stimulation of B Lymphocytes

1992 541 citations Robert H. Carter, Douglas T. Fearon Science profile →
Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase.

1975 358 citations Douglas T. Fearon et al. The Journal of Experimental Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Douglas T. Fearon United States	76	15.2k	6.6k	5.4k	3.0k	2.7k	178	24.5k
David Cosman United States	81	17.8k 1.2×	7.7k 1.2×	9.1k 1.7×	3.3k 1.1×	1.5k 0.5×	151	28.7k
Lee M. Nadler United States	79	14.5k 1.0×	6.5k 1.0×	5.1k 0.9×	3.6k 1.2×	4.0k 1.5×	268	24.6k
Thomas F. Tedder United States	113	26.9k 1.8×	7.0k 1.1×	8.0k 1.5×	2.6k 0.9×	5.3k 1.9×	342	41.1k
Andreas Radbruch Germany	96	19.0k 1.2×	3.5k 0.5×	6.8k 1.3×	2.3k 0.8×	4.2k 1.5×	440	30.8k
Ethan M. Shevach United States	104	37.5k 2.5×	7.3k 1.1×	6.6k 1.2×	1.9k 0.7×	3.5k 1.3×	423	47.7k
Dennis A. Carson United States	88	11.1k 0.7×	5.7k 0.9×	11.4k 2.1×	1.5k 0.5×	4.2k 1.6×	467	29.3k
Edgar G. Engleman United States	78	15.5k 1.0×	5.8k 0.9×	6.0k 1.1×	1.3k 0.4×	2.1k 0.8×	277	24.9k
Cox Terhorst United States	77	15.4k 1.0×	3.7k 0.6×	4.9k 0.9×	3.1k 1.0×	3.2k 1.2×	267	21.3k
Raif S. Geha United States	99	19.4k 1.3×	2.7k 0.4×	5.3k 1.0×	2.4k 0.8×	2.3k 0.8×	501	31.8k
Herbert C. Morse United States	81	12.1k 0.8×	3.6k 0.5×	8.0k 1.5×	1.7k 0.6×	1.6k 0.6×	437	22.8k

Countries citing papers authored by Douglas T. Fearon

Since Specialization

Citations

This map shows the geographic impact of Douglas T. Fearon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas T. Fearon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas T. Fearon more than expected).

Fields of papers citing papers by Douglas T. Fearon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas T. Fearon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas T. Fearon. The network helps show where Douglas T. Fearon may publish in the future.

Co-authorship network of co-authors of Douglas T. Fearon

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas T. Fearon. A scholar is included among the top collaborators of Douglas T. Fearon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas T. Fearon. Douglas T. Fearon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Maia-Silva, Diogo, Damianos Skopelitis, Yuan Gao, et al.. (2024). Interaction between MED12 and ΔNp63 activates basal identity in pancreatic ductal adenocarcinoma. Nature Genetics. 56(7). 1377–1385. 6 indexed citations

Li, Jiayun, et al.. (2024). Intratumoral NKT cell accumulation promotes antitumor immunity in pancreatic cancer. Proceedings of the National Academy of Sciences. 121(29). e2403917121–e2403917121. 2 indexed citations

Yao, Min, Jonathan Preall, Johannes T.‐H. Yeh, et al.. (2023). Plasma cells in human pancreatic ductal adenocarcinoma secrete antibodies against self-antigens. JCI Insight. 8(21). 6 indexed citations

Yan, Ran, et al.. (2023). T cell–Mediated Development of Stromal Fibroblasts with an Immune-Enhancing Chemokine Profile. Cancer Immunology Research. 11(8). 1044–1054. 11 indexed citations

Fein, Miriam R., Xue‐Yan He, Ana S. Almeida, et al.. (2020). Cancer cell CCR2 orchestrates suppression of the adaptive immune response. The Journal of Experimental Medicine. 217(10). 45 indexed citations

Pommier, Arnaud, Naishitha Anaparthy, Zakiya Kelley, et al.. (2018). Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases. Science. 360(6394). 197 indexed citations

Goncalves, Marcus D., Seo‐Kyoung Hwang, Chantal Pauli, et al.. (2018). Fenofibrate prevents skeletal muscle loss in mice with lung cancer. Proceedings of the National Academy of Sciences. 115(4). E743–E752. 85 indexed citations

Arnold, James N., Łukasz Magiera, Matthew Kraman, & Douglas T. Fearon. (2013). Tumoral Immune Suppression by Macrophages Expressing Fibroblast Activation Protein-α and Heme Oxygenase-1. Cancer Immunology Research. 2(2). 121–126. 136 indexed citations

Thaventhiran, James, Anja Hoffmann, Łukasz Magiera, et al.. (2012). Activation of the Hippo pathway by CTLA-4 regulates the expression of Blimp-1 in the CD8 ⁺ T cell. Proceedings of the National Academy of Sciences. 109(33). E2223–9. 65 indexed citations

10.

Kraman, Matthew, James N. Arnold, Edward W. Roberts, et al.. (2010). Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α. Science. 330(6005). 827–830. 918 indexed citations breakdown →

11.

Bannard, Oliver, Matthew Kraman, & Douglas T. Fearon. (2009). Secondary Replicative Function of CD8 ⁺ T Cells That Had Developed an Effector Phenotype. Science. 323(5913). 505–509. 129 indexed citations

12.

Thaventhiran, James, et al.. (2006). CD27 mediates interleukin-2-independent clonal expansion of the CD8 ⁺ T cell without effector differentiation. Proceedings of the National Academy of Sciences. 103(51). 19454–19459. 53 indexed citations

13.

Otaki, Joji M., Douglas T. Fearon, & Haruhiko Yamamoto. (2005). The proto-oncogene BCL-6 is expressed in olfactory sensory neurons. Neuroscience Research. 53(2). 189–200. 11 indexed citations

14.

Fougerolles, Antonin R. de, Facundo D. Batista, Eskil Johnsson, & Douglas T. Fearon. (2001). IgM and stromal cell-associated heparan sulfate / heparin as complement-independent ligands for CD19. European Journal of Immunology. 31(7). 2189–2199. 31 indexed citations

15.

Tooze, Reuben, Martin Turner, David Sandoval, et al.. (1998). CD19 as a Membrane-Anchored Adaptor Protein of B Lymphocytes: Costimulation of Lipid and Protein Kinases by Recruitment of Vav. Immunity. 8(5). 635–645. 155 indexed citations

16.

Fearon, Douglas T. & J M Ahearn. (1990). Complement Receptor Type 1 (C3b/C4b Receptor; CD35) and Complement Receptor Type 2 (C3d/Epstein-Barr Virus Receptor; CD21). Current topics in microbiology and immunology. 153. 83–98. 45 indexed citations

17.

Wong, W. Wei‐Lynn, Christine Kennedy, Margaret J. Morris, et al.. (1989). Structure of the human CR1 gene. Molecular basis of the structural and quantitative polymorphisms and identification of a new CR1-like allele.. The Journal of Experimental Medicine. 169(3). 847–863. 80 indexed citations

18.

Wilson, James G., Ellen Murphy, W. Wei‐Lynn Wong, et al.. (1986). Identification of a restriction fragment length polymorphism by a CR1 cDNA that correlates with the number of CR1 on erythrocytes.. The Journal of Experimental Medicine. 164(1). 50–59. 143 indexed citations

19.

Kazatchkine, Michel D., Douglas T. Fearon, & K. Frank Austen. (1979). Human Alternative Complement Pathway: Membrane-Associated Sialic Acid Regulates the Competition between B and β1H for Cell-Bound C3b. The Journal of Immunology. 122(1). 75–81. 234 indexed citations

20.

Fearon, Douglas T.. (1978). Activation of the Alternative Complement Pathway by Escherichia Coli: Resistance of Bound C3b to Inactivation by C3bINA and β1H. The Journal of Immunology. 120(5). 1772–1772. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact